美國Quidel公司(Quidel Corporation),成立于1979年，總部位于美國,連同其附屬公司，從事傳染病點(diǎn)保健和生殖與婦女健康的診斷解決方案的開發(fā)，制造及銷售。公司現(xiàn)擁有員工共322人。是一家在美國納斯達(dá)克上市的綜合性臨床診斷產(chǎn)品生產(chǎn)商和健康服務(wù)研發(fā)型企業(yè),股票代碼:(Nasdaq: QDEL)，其部分快速診斷產(chǎn)品占據(jù)美國主流市場。主要產(chǎn)品包括傳染性疾病的診斷、生殖健康及孕期診斷、癌癥輔助診斷、骨質(zhì)疏松癥輔助診斷及自身免疫疾病的輔助診斷，旗下品牌主要有：Metra， Quidel ， QuickVue ，QuickVue In-Line ，QuickVue Advance，QuickVue+，RapidVue 等。

主營業(yè)務(wù)內(nèi)容 其他產(chǎn)品：免疫大便潛血試驗(yàn)，幽門螺旋桿菌測試，臨床實(shí)驗(yàn)和研究試驗(yàn)

生殖和婦女的健康：包括懷孕，衣原體，細(xì)菌性陰道病和骨骼健康

傳染病產(chǎn)品：如流感， A組鏈球菌和呼吸道合胞病毒

Quidel Corporation (Nasdaq: QDEL) is a leader serving to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health.

Our products provide healthcare professionals with accurate and cost-effective diagnostic information at the POC. We sell our products to professionals for use in physician's offices, hospitals, clinical laboratories, and wellness screening centers. Our products are focused substantially on family health in areas such as pregnancy, infectious diseases, general health screening, oncology, bone health and autoimmune disorders.

Quidel commenced operations in 1979 and we launched our first products, dipstick-based pregnancy tests, in 1984. Our product base and technology platforms have expanded through internal development and acquisitions of other products and technologies. The current product areas are pregnancy, infectious diseases, oncology, autoimmune diseases and osteoporosis, for professional and research use. During the early 1990's, Quidel successfully embarked on a mission to build its own branded business and market franchises in the professional use markets. As a result, sales are primarily driven by our branded business under the QuickVue? brand name, and the Company enjoys excellent product recognition in its target markets.

The Company continues to increase its research and development efforts and to accelerate the rate of new product introductions. In January 2006, we launched our QuickVue? iFOB (immunochemical Fecal Occult Blood) test for the qualitative detection of blood in stool. Blood in stool is an indication of a number of gastrointestinal disorders, including colorectal cancer.

The strength of Quidel's international distribution strategy is reflected in the success of QuickVue? Rapid SP Influenza in Japan, the world's second largest flu market. We are extending the QuickVue? brand in select Asian and European markets, and will use the Japanese market as a template for penetrating additional countries with appropriate products. We sell through sales representatives for Europe, Middle East, Africa, Asia-Pacific, Latin America and, other international locations, by channeling products through distributor organizations and sales agents. We market our products in the U.S. through a network of national and regional distributors, supported by a direct sales force, and were pleased to be recognized by three of the largest U.S. medical supply distributors as "Supplier of the Year" within the last year.

訂貨請(qǐng)上海起發(fā)實(shí)驗(yàn)試劑有限公司 
：4006551678  企業(yè)：4006551678   ：fige007
更多產(chǎn)品請(qǐng)我們

正規(guī)代理品牌：Polysciences Inc ，AB Biolabs ，abbexa ，Acris Antibodies ，arcticzymes ，AROTEC ，Athens ，Aves Labs, Inc. Bangs Laboratories ，BBI ， bellbrooklabs ，biomatik ，Biorelevant ，Biosearch ，chiralix ，Columbia Biosciences ，Crystal chem ，Dianova Enzyme Research ，FD NEURO ，FITZGRALD ，FormuMax ，Gelcompany Gene Bridges GmbH ，Glycotope，Hyglos GmbH ，iduron ，Immudex ，immunoGlob，Innovative Research ，iris-biotech ，kalenbiomed ，Ludger ，Microspheres-nanosphere ，Mybiosource ，nanocomposix ，nanotools ，Neuro Probe ，nibsc ，OLIGOENGINE ，pentapharm ，ProQinase ，prospec ，QA-Bio,Inc ，QuickZyme Biosciences ，researchdiets ，anta Cruz,  springbio ，synaptic system ，TriLink BioTechnologies, Inc. ，Viagen Biotech ，Immunologic  Corporation ，Zyagen Laboratories ，ZYGEM Corp Ltd，Alomone，medicago，BIOCHAIN